Prognostic Factors for Intraoperative 125I Seeds Implantation for Treatment of Locally-Advanced Pancreatic Carcinoma

Wang, H.; Junjie, W.; Yuliang, J.; Jinna, L.; Tian, Suqing; Ran, Weiqiang; Xiu, Dianrong; Yang, Guang

doi:10.1016/j.ijrobp.2013.06.814

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median tumour dose ranged from 52 Gy 55 to 167 Gy 53 , with most of the studies ranging between 100 and 150 Gy. For the application method, 14 studies (542 patients) implanted the seeds intraoperatively in an open approach using X-ray, CT, or ultrasonography guidance 27 , 28 , 30 , 34–36 , 38 , 40 , 44 , 46 , 48 , 50 , 51 , 54 . Twelve studies (401 patients) used percutaneous implantation guided by ultrasonography or CT 25 , 26 , 31 , 32 , 39 , 43 , 45 , 49 , 52 , 53 , 55 , 56 .…”

Section: Resultsmentioning

confidence: 99%

Intratumoral injection therapies for locally advanced pancreatic cancer: systematic review

Willink,

Jenniskens,

Klaassen

et al. 2023

BJS Open

View full text Add to dashboard Cite

Introduction Pancreatic cancer has one of the worst prognoses of all cancers. Patients with locally advanced pancreatic cancer have a 12.7–20.2 per cent chance of receiving curative surgery after induction systemic chemotherapy. Intratumoral injection therapies have been studied as complementary treatment options for improved local tumour control. The aim of this systematic review was to provide an overview of intratumoral injection therapies, their safety, and oncological outcome in patients with locally advanced pancreatic cancer. Methods A literature search was conducted in PubMed, Embase and the Cochrane Library for articles written in English up to 28 November 2022. All study designs involving at least five patients with locally advanced pancreatic cancer who were treated with an intratumoral injection therapy were included. Critical appraisal of the included studies was performed using the Newcastle–Ottawa scale. Results After evaluation of the 1680 articles yielded by the systematic search, 52 studies treating 1843 patients were included. Included intratumoral injection treatment modalities comprised iodine-125 (125I) seed brachytherapy (32 studies, 1283 patients), phosphorus-32 (32P) microbrachytherapy (5 studies, 133 patients), palladium-103 (103Pd) seed brachytherapy (2 studies, 26 patients), immunotherapy (9 studies, 330 patients), and chemotherapy (4 studies, 71 patients). Overall survival ranged between 7.0 and 16.0 months for 125I, 5.2 and 15.5 months for 32P, 6.9 and 10.0 months for 103Pd, 5.8 and 13.8 months for immunotherapy, and 9.0 and 16.2 months for chemotherapy. Severe complication (greater than or equal to grade III complications using Clavien–Dindo classification) rates were 6.2 per cent for 125I, 49.2 per cent for 32P, 15 per cent for 103Pd, 57.9 per cent for immunotherapy, and 0 per cent for chemotherapy. Conclusion Five intratumoral injection therapies are described and an overview is reported. Some intratumoral injection therapies for patients with locally advanced pancreatic cancer seem safe, although 32P microbrachytherapy and immunotherapy require additional evidence. Currently available data are insufficient to provide firm conclusions regarding the added value to survival. The potential advantage of intratumoral injection therapies complementary to conventional care should be studied in well designed RCTs.

show abstract